On April 7, 2023 HiFiBiO Therapeutics, a clinical-stage multinational biotherapeutics company, reported that its scientific work in exploring approaches to target the TIGIT/CD226 axis has been selected for oral presentation at the AACR (Free AACR Whitepaper) 2023 meeting during April 14-19, 2023, in Orlando, FL (Press release, HiFiBiO Therapeutics, APR 7, 2023, View Source [SID1234629882]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"To date, the industry has struggled to successfully develop therapeutics targeting TIGIT, both as a monotherapy and in combination with anti-PD-1/PD-L1 blockers to effectively stimulate the CD226 axis. We believe the next generation of therapies modulating the CD226 axis will need to target additional immune receptors in the axis," said Jinping Gan, VP Global Head of Research at HiFiBiO Therapeutics. "Through our single cell driven DIS platform, we have made great progress developing multi-specific approaches for CD226 axis immune modulation in addition to understanding the single cell biology in the tumor microenvironment for indication selection and predictive biomarkers."
"Beyond our three immune-oncology clinical programs targeting TNFR2, OX40, and BTLA, we continue to explore how the HiFiBiO DIS approach can transform the drug discovery and development paradigm by integrating deep understanding of immune modulation with a world-leading single cell platform and machine learning-enabled data analysis," said Francisco Adrian, Chief Scientific Officer of HiFiBiO Therapeutics.
Details on the oral presentation are as follows:
Title: Maximizing the outcome of CD226 stimulation through targeting beyond TIGIT signaling with combination and multi-specific approaches for cancer and immunotherapy
Presenter: Jinping Gan, Ph.D., Vice President, Global Head of Research
Session Title: Immune Checkpoints at Tumor Beds
Session Date and Time: Monday, April 17, 2023; 2:30 pm – 4:30 pm
Venue: Valencia D – Convention Center